ReviewCurrent hematologic malignancy reports2026

New Approaches for Measurable Residual Disease Assessment in Multiple Myeloma: Integrating NGS, Mass Spectrometry, and Next-Generation Flow Cytometry to Monitor Treatment Response.

Bhavesh Mohan Lal et al.PubMed ↗Publisher ↗

No numbers read from the abstract.